Want to see FATE full AI Analyst Report?
FATE Stock Chart & Stats
$1.39
-$0.10(-5.71%)
At close: 4:00 PM EST
$1.39
-$0.10(-5.71%)
Day’s Range― - ―
52-Week Range$0.91 - $2.88
Previous CloseN/A
Volume630.90K
Average Volume (3M)3.95M
Market Cap
$244.77M
Enterprise Value$265.67M
Total Cash (Recent Filing)$174.82M
Total Debt (Recent Filing)$76.78M
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Aug 05, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding116,559,190
10 Day Avg. Volume2,614,129
30 Day Avg. Volume3,950,607
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)17.56
P/FCF Ratio-1.04
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue42.06
Enterprise Value/Gross Profit-10.12
Enterprise Value/Ebitda-2.26
Forecast
1Y Price Target
$5.24Price Target Upside277.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$5.25M
Bulls Say, Bears Say
Bulls Say
Scalable IPSC-based PlatformFate’s iPSC-based, off-the-shelf manufacturing model is a durable structural advantage: a single run can supply multiple patients, supporting lower marginal costs, faster supply scaling and outpatient-enabled therapies. This underpins long-term commercial leverage if clinical success is achieved.
Advancing CAR‑T Autoimmune PipelineProgress to a planned registrational Phase 2 (RECLAIM-LN) and multiple next‑generation candidates signals maturation from discovery to later-stage development. Moving programs into registrational paths materially increases the company’s potential to de‑risk clinical assets and support eventual commercialization planning.
Shareholder And Governance SupportStockholder approval of directors and an expanded equity plan provides governance stability and explicit authorization for equity-based financing or incentives. This structural support improves the company’s ability to secure needed capital and align management with long‑term development objectives.
Bears Say
Heavy Cash BurnSustained, large negative operating and free cash flow creates ongoing financing dependency. Over the next 2–6 months this elevates dilution and execution risk for multi-site trials and manufacturing scale-up, forcing management to secure additional capital or cut spending.
Small, Declining Revenue And Negative MarginsMinimal and shrinking revenue with negative gross profit reflects limited commercial validation and persistent pre‑revenue biology. Large losses and negative margins indicate the business remains development‑stage and reliant on external funding, constraining self‑sufficiency and margin improvement near term.
Shrinking Equity BaseA materially reduced equity base from cumulative losses weakens the balance-sheet cushion and reduces capacity to absorb more operating deficits. Even with modest leverage today, continued losses could force dilutive financings or limit strategic optionality over the coming quarters.
Fate Therapeutics News
FATE FAQ
What was Fate Therapeutics Inc’s price range in the past 12 months?
Fate Therapeutics Inc lowest stock price was $0.91 and its highest was $2.88 in the past 12 months.
What is Fate Therapeutics Inc’s market cap?
Fate Therapeutics Inc’s market cap is $244.77M.
When is Fate Therapeutics Inc’s upcoming earnings report date?
Fate Therapeutics Inc’s upcoming earnings report date is Aug 05, 2026 which is in 37 days.
How were Fate Therapeutics Inc’s earnings last quarter?
Fate Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.02.
Is Fate Therapeutics Inc overvalued?
According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued.
Does Fate Therapeutics Inc pay dividends?
Fate Therapeutics Inc does not currently pay dividends.
What is Fate Therapeutics Inc’s EPS estimate?
Fate Therapeutics Inc’s EPS estimate is -0.27.
How many shares outstanding does Fate Therapeutics Inc have?
Fate Therapeutics Inc has 116,559,190 shares outstanding.
What happened to Fate Therapeutics Inc’s price movement after its last earnings report?
Fate Therapeutics Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -5.111%.
Which hedge fund is a major shareholder of Fate Therapeutics Inc?
Currently, no hedge funds are holding shares in FATE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.24 (277.18% Upside)
$5.24 (277.18% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 188.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $102.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.90%
12-Months-Change
Fundamentals
Return on Equity
-58.89%
Trailing 12-Months
Asset Growth
-28.53%
Trailing 12-Months
Company Description
Fate Therapeutics Inc
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
FATE Stock 12 Month Forecast
Average Price Target
$5.24
▲(277.18% Upside)
Technical Analysis
Ownership Overview
12.84% Insiders
12.63% Mutual Funds
19.21% Other Institutional Investors
46.73% Public Companies and
Individual Investors